Document Detail


Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer.
MedLine Citation:
PMID:  15655934     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pemetrexed (Alimta) possesses broad antitumor activity. It has been evaluated in non-small-cell lung cancer (NSCLC) as front-line chemotherapy in a comprehensive phase II evaluation. While various antifolates have been previously evaluated in clinical trials, drug development was stopped or delayed in light of their lack of efficacy or occurrence of life-threatening toxicities. While similar trends were observed with pemetrexed early in development, investigators instituted folic acid and vitamin B12 supplementation to minimize these toxicities without hampering drug efficacy. This article briefly summarizes the current evidence that supports the role of pemetrexed-based combinations in clinical trials for chemonaive patients with advanced NSCLC.
Authors:
Giorgio V Scagliotti; Silvia Novello; Lucio Crino; Rafael Rosell
Related Documents :
17205204 - Pharmacotherapy for fecal incontinence: a review.
20348494 - Treatment with coartem (artemether-lumefantrine) in papua new guinea.
20401974 - Mutation-driven drug development in melanoma.
15544204 - Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations ...
21711774 - Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(la...
14708054 - Special wound healing methods used in ancient egypt and the mythological background.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Oncology (Williston Park, N.Y.)     Volume:  18     ISSN:  0890-9091     ISO Abbreviation:  Oncology (Williston Park, N.Y.)     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2005-01-19     Completed Date:  2005-02-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712059     Medline TA:  Oncology (Williston Park)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  32-7     Citation Subset:  IM    
Affiliation:
University of Torino, Department of Clinical & Biological Sciences, S. Luigi Gonzaga Thoracic Oncology Unit, Orbassano (Torino), Italy. giorgio.scagliotti@unito.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Cisplatin / administration & dosage
Clinical Trials, Phase II as Topic
Female
Folic Acid Antagonists / administration & dosage*
Glutamates / administration & dosage*
Guanine / administration & dosage*,  analogs & derivatives*
Humans
Lung Neoplasms / drug therapy*,  pathology
Neoplasm Metastasis
Thymidylate Synthase / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Folic Acid Antagonists; 0/Glutamates; 137281-23-3/pemetrexed; 15663-27-1/Cisplatin; 73-40-5/Guanine; EC 2.1.1.45/Thymidylate Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pemetrexed in malignant pleural mesothelioma.
Next Document:  Pemetrexed in second-line treatment of non-small-cell lung cancer.